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Background: We investigated the efficacy and safety of S-1 and cisplatin with concurrent thoracic radiation (SCCR)
over cisplatin alone plus concurrent thoracic radiation (CCR) for unresectable stage III non-small-cell lung cancer
(NSCLC).
Methods: Between January 2009 and November 2011, 40 eligible patients with NSCLC were included and divided
randomly into two groups. Twenty patients received SCCR with S-1 (orally at 40 mg/m2 per dose, b.i.d.) on days 1
through 14, cisplatin (60 mg/m2 on day 1) every 4 weeks for two cycles, and radiotherapy (60 Gy/30 fractions over
6 weeks) beginning on day 1. Twenty subjects received CCR (cisplatin and radiotherapy, the same as for SCCR).
Results: The 3-year overall response rate was 59.3% and 52.4% for the SCCR and CCR groups, respectively, and the
difference was statistically significant, while the median overall survival was 33 months (range, 4–41 months) and
24 months (range, 2–37 months), respectively (P = 0.048). The median progression-free survival was 31 months for
SCCR (range, 5–39 months), whereas it was 20 months (range, 2–37 months) for CCR (P = 0.037). The toxicity profile
was similar in both groups.
Conclusion: In summary, we demonstrated that S-1 and cisplatin with concurrent thoracic radiation was more
effective than cisplatin plus radiotherapy in NSCLC patients with acceptable toxicity.
Trial registration: Chinese Clinical Trials Register: ChiCTR-TRC-13003997.
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Non-small-cell lung cancer (NSCLC) accounts for 80%
of all lung cancer cases, and approximately 30% of
all lung cancer patients are diagnosed with stage III
disease [1], for which the standard treatment is concurrent
chemoradiotherapy [2]. Recent randomized phase III trials
have shown that concurrent chemoradiotherapy is
superior to chemotherapy followed by radiotherapy in
terms of response and survival in these patients [3,4].
However, concurrent chemoradiotherapy is also associated* Correspondence: shidongxu0451@163.com
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unless otherwise stated.with greater acute toxicity, which includes bone marrow
suppression and esophagitis, than sequential chemora-
diotherapy [5].
S-1 (TS-1, Taiho Pharmaceutical Co., Ltd) is a new
oral fluoropyrimidine agent designed to enhance anti-
cancer activity and to reduce gastrointestinal toxicity.
It consists of tegafur (a 5-FU Pro-drug), 5-chloro-2, 4-
dihydroxypyridine (an inhibitor of dihydropyrimidine
dehydrogenase), and potassium oxonate (an inhibitor
of phosphoribosyl transferase), in a molar ratio of
1:0.4:1. S-1 has been shown to induce a comparable
response to the other single agents for metastatic
NSCLC [6]. Two studies of S-1 plus cisplatin for
advanced NSCLC showed a response rate of 32.7–47%
and a median survival time of 11–16 months. Theseis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tinal or hematological toxicities [7,8].
To date, there have been no reported randomized con-
trolled trials to assess the efficacy and safety of S-1 plus
cisplatin with concurrent radiotherapy (SCCR) versus
cisplatin plus concurrent thoracic radiation (CCR) for
stage III NSCLC. Therefore, more rigorous studies are
required to elucidate the feasibility and efficacy of S-1
for the treatment of these patients.
We conducted a single-center, randomized controlled
pilot study to evaluate the feasibility and efficacy of S-1
plus cisplatin with concurrent radiotherapy for treating
NSCLC patients. The results of this study will also help




Patient eligibility requirement for enrollment in this
study was cytologically or histologically confirmed,
unresectable stage IIIA or IIIB NSCLC, diagnosed
between January 2009 and November 2011. The clin-
ical or pathologic stage of the disease was determined
based on the general rules for the TNM Classification
of Malignant Tumors (6th edition) [9]. The other
eligibility criteria were an age between 20 and 80 years,
Eastern Cooperative Oncology Group performance
status of 0 or 1, no previous chemotherapy or radio-
therapy, and adequate hematologic, hepatic, and renal
function. Patients also had to have the following
standard laboratory test results: a leukocyte count of
4000–12 000/μl, a platelet count of ≥100 000/μl, a
hemoglobin level of ≥9 g per 100 ml, a serum bilirubin
level of ≤1.5 mg per 100 ml, serum aspartate ami-
notransferase and alanine aminotransferase levels of
≤100 IU/ml, an alkaline phosphatase level of no more
than twice the upper limit of normal, a normal cre-
atinine level, and a partial pressure of arterial oxygen
of ≥65 torr in room air. All eligible patients underwent
computed tomography (CT) scans of the thorax, including
the upper abdomen, and a radioisotopic bone scan.
Patients who were pregnant or who had malignant
pleural effusion, malignant pericardial effusion, a con-
comitant malignancy, or serious comorbidities such as
clinically significant cardiac dysfunction, active infection,
or neurologic or psychiatric disorders were excluded from
the study. The study was approved by the institutional
ethics committee of Third Affiliated Hospital of Harbin
Medical University with permission number (KY2009-41).
The randomization code was generated using a com-
puterized number generator through the stratified block
randomization method of the SAS package (Version
9.1.3; SAS Institute Inc., Cary, North Carolina, USA) by
a statistician with no clinical involvement in this study.After qualifying, patients were assigned to either of two
treatment groups: SCCR group or CCR group. The allo-
cation was concealed in sequentially numbered, opaque,
sealed envelopes containing the randomization assign-
ments. In addition, all the outcome assessors and data
analysts were blinded in this study.
Treatment schedule
A CT scan of the chest tumor was conducted in order
to determine tumor volume before therapy. Patients in
the CCR group received cisplatin (60 mg/m2) on day 1
and then at 4-week intervals, and they also underwent
radiotherapy, which was administrated concurrently
on day 1 by chest irradiation. Two different radiation
target volumes were planned. The initial dose (approxi-
mately 40 Gy) was administered to the primary tumor,
the ipsilateral hilum with a 2-cm margin, and the in-
volved mediastinal lymph nodes with a 1-cm margin.
Prophylactic radiation fields were not planned, except
for subcarinal lymph nodes. Subsequently, a 20 Gy dose
was given as a booster once a day for 5 days each week
over a period of 6 weeks using a linear accelerator gen-
erating at least 4 MeV photons, in accordance with
tumor shrinkage. In addition to receiving the same
intervention as the CCR group, patients in the SCCR
group were also administered S-1 (orally at 40 mg/m2
per dose, b.i.d., on days 1 through 14).
Evaluation of response and toxicity
All eligible patients who received treatment were
considered assessable for response and toxicity mea-
sures. Chest radiography, complete blood counts,
and blood chemistry measurements were performed
weekly during the treatment period. The response
was assessed according to the Response Evaluation
Criteria in Solid Tumors (RECIST) [10]. The toxicity
for all patients who received any treatment was eval-
uated and graded according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events, Version 3.0 [11].
Statistical analysis
An intention to treat analysis was performed. Progression-
free survival (PFS) was defined as the time from the
starting date of induction chemoradiotherapy until
disease progression or death. Patients whose disease
had not progressed at the time of study treatment
discontinuation continued to be assessed until pro-
gression was documented. Overall survival (OS) was
defined as the time from the starting date of induction
chemoradiotherapy until death from any cause. Sample
size was calculated on the basis of an expected 15%
difference between the 2 groups. OS was calculated
from the day of randomization to the day of death. Data
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which they were last known to be alive. PFS was com-
puted from the date of randomization to the date of
relapse, death, or completion of follow-up, whichever
occurred first. Data on patients who were alive and pro-
gression free were censored at the time of the last
follow-up visit. OS and PFS rates were calculated using
the Kaplan–Meier method, and P ≤ 0.05 was considered
statistically significant. All P values were obtained using
2-tailed t-tests.
Results
In this study, 85 subjects were initially screened, of
whom 45 were excluded. Of these 45 patients, 39 did
not meet the study criteria and 6 declined to parti-
cipate. The remaining 40 patients (20 treated with
SCCR, and 20 treated with CCR) were entered into
the study between January 2009 and November 2011.
All patients could be assessed for efficacy and safety
(Figure 1).
The baseline characteristics of the patients were simi-
lar in the two treatment groups (Table 1). The mean
age was 59.6 years in the SCCR group and 60.4 years
in the CCR group. The performance status was 0 for
65.0% of patients treated with SCCR and 60.0% of
patients treated with CCR, and it was 1 for 35.0% of
patients treated with SCCR and 40.0% of patients
treated with CCR. Histological examinations indicated
the presence of the following cancer cell types: adeno-
carcinoma (45.0% in the SCCR group and 50.0% in the
CCR group), squamous (35.0% in the SCCR group andFigure 1 Flow of participants through the trial.25.0% in the CCR group), and large cell carcinoma
(20.0% in the SCCR group and 25.0% in the CCR
group). The disease stage was IIIA (80.0% in the SCCR
group and 70.0% in the CCR group) or IIIB (20.0% in
the SCCR group and 30.0% in the CCR group). In total,
30 of 40 (75.0%) patients had stage IIIA disease and 10
of 40 (25.0%) patients had stage IIIB disease. The
primary tumor was located in the upper lobe in 13 and
15 patients and in other lobes in 7 and 5 patients
treated with SCCR and CCR, respectively.
The overall response rate as determined by the
RECIST criteria was 59.3% for SCCR and 52.4%
for CCR; the difference was statistically significant
(P < 0.05; Table 2). The median OS was 33 months
(range, 4–41 months) and 24 months (range, 2–37
months) for the SCCR and CCR groups, respectively
(P = 0.048; Figure 2). In addition, the median PFS was
31 months and 20 months for the SCCR (range, 5–39
months) and CCR groups (range, 2–37 months),
respectively (P = 0.037; Figure 3).
All of the AEs that occurred in each group are listed
in Table 2. The major hematological toxicities were
leucopenia (25.0% in the SCCR group and 20.0% in
the CCR group), thrombocytopenia (20.0% in both the
SCCR and CCR groups), neutropenia (20.0% in the
SCCR group and 15.0% in the CCR group), febrile
neutropenia (15.0% in both the SCCR and CCR groups),
and anemia (15.0% in the SCCR group and 10.0% in
the CCR group). The most common grade 3 or 4 non-
hematological toxicities were anorexia (15.0% in the
SCCR group and 10.0% in the CCR group), nausea
Table 1 Baseline characteristics of participants at trial entry: ITT population
Variable SCCR (n = 20) CCR (n = 20) P value
Age, yrs: mean (SD) 59.6 (19.3) 60.4 (20.1) 0.90
Race Asian (Chinese) 20 (100.0%) 20 (100.0%) 1.00
Sex
Males 15 (75.0%) 14 (70.0%) 0.72
Females 5 (25.0%) 6 (30.0%) 0.72
Performance status
0 13 (65.0%) 12 (60.0%) 0.74
1 7 (35.0%) 8 (40.0%) 0.74
Histology
Adenocarcinoma 9 (45.0%) 10 (50.0%) 0.75
Squamous cellcarcinoma 7 (35.0%) 5 (25.0%) 0.49
Large cell carcinoma 4 (20.0%) 5 (25.0%) 0.71
Stage of disease
IIIA 16 (80.0%) 14 (70.0%) 0.47
IIIB 4 (20.0%) 6 (30.0%) 0.47
Primary site
Upper lobe 13 (65.0%) 15 (75.0%) 0.49
Middle/lower lobe 7 (35.0%) 5 (25.0%) 0.49
Note: ITT, intent-to-treat; SCCR, S-1, cisplatin and concurrent thoracic radiation; CCR, cisplatin and concurrent thoracic radiation; yrs, years; SD, standard deviation.
Yao et al. Radiation Oncology  (2015) 10:10 Page 4 of 6(10.0% in both the SCCR and CCR groups), constipation
(10.0% in both the SCCR and CCR groups), and esopha-
gitis (10.0% in the SCCR group and 5.0% in the CCR
group). There were no treatment-related deaths in ei-
ther group.Table 2 Summary of adverse events
Adverse events SCCR (n = 20) CCR (n = 20)
G3/4 (≥G3) (%) G3/4 (≥G3) (%)
Haematolgic
Leukopenia 4/1 (25.0%) 3/1 (20.0%)
Thrombocytopenia 4/0 (20.0%) 3/1 (20.0%)
Neutropenia 4/0 (20.0%) 3/0 (15.0%)
Febrile neutropenia 3/0 (15.0%) 3/0 (15.0%)
Anaemia 3/0 (15.0%) 2/0 (10.0%)
Non-haematolgic
Anorexia 3/0 (15.0%) 2/0 (10.0%)
Nausea 1/1 (10.0%) 2/0 (10.0%)
Constipation 2/0 (10.0%) 2/0 (10.0%)
Oesophagitis 2/0 (10.0%) 1/0 (5.0%)
Fatigue 1/0 (5.0%) 2/0 (10.0%)
ALT, AST 1/0 (5.0%) 0/0 (0%)
Pneumonitis 1/0 (5.0%) 0/0 (0%)
Diarrhoea 0/0 (0%) 1/0 (5.0%)Discussion
This is the first pilot randomized controlled study to
investigate the use of the oral fluoropyrimidine agent
S-1 as a consolidation drug in chemoradiotherapy for
stage III NSCLC. Our data indicated reasonable survival
with a median survival time of 21.8 months and a three-
year survival rate of 34.0%. In addition, tumor response
was demonstrated to be 61.5%. However, less than half
of the patients completed this regimen (47.6%) and it is
unlikely that this treatment is feasible.
Previous studies showed that chemoradiotherapy with
cisplatin resulted in high response and survival rates in
patients with stage III NSCLC. A phase I trial reported a
median survival time of 30.4 months with a three-year
survival rate of 50% in 18 patients [12], and a retrospect-
ive study showed a median survival time of 21 months
and a three-year survival rate of 33% in 73 patients with
a median of 2 chemotherapy cycles (mean, 2.4 cycles;
range, 1–3 cycles) [13]. A multi-institutional phase II
trial of S-1 after concurrent chemoradiotherapy with
cisplatin and vinorelbine for locally advanced NSCLC
revealed a response rate of 61.5%, a median PFS of
10.2 months (95% confidence interval [CI], 8.6–13.7 months),
and a median survival time of 21.8 months (95% CI,
15.6–27.6 months). In addition, the 1- and 3-year sur-
vival rates were 73.9% and 34.0%, respectively [14].
SCCR also had a favorable safety profile in this study.
The overall frequency of AEs was similar in both groups
Figure 2 Overall survival.
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of both drug-related AEs and severe AEs were higher in
the SCCR group than in the CCR group.
Our study has several strengths. First, the trial was
randomized thereby reducing selection bias. Second,
although there was no consensus regarding the appro-
priate dose of SCCR for patients with locally advanced
NSCLC, the dose used in our study was within theFigure 3 Progression-free survival.therapeutic range. Further studies with a larger sample
size and longer duration of SCCR treatment are needed
to further confirm the results of this study.
In conclusion, the results of this study demonstrate
promising efficacy and a very acceptable toxicity profile
for SCCR in patients with locally advanced NSCLC. Des-
pite the short follow-up period, these encouraging clinical
and pathological results warrant further investigation.
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